Determining the subjective effects of TFMPP in human males

Psychopharmacology

Volumn 211, Issue 3, 2010, Pages 347-353

  Jan, Reem K ^a   Lin, Joanne C ^a   Lee, Heeseung ^a   Sheridan, Janie L ^a   Kydd, Rob R ^a   Kirk, Ian J ^b   Russell, Bruce R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Human; Mood; Party pills; Piperazine; Trifluoromethylphenyl piperazine (TFMPP)

Indexed keywords

1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 1-(3-TRIFLUOROMETHYLPHENYL)PIPERAZINE; PIPERAZINE DERIVATIVE; PSYCHEDELIC AGENT; SEROTONIN AGONIST; STREET DRUG;

ADDICTION RESEARCH CENTER INVENTORY; ARTICLE; CONFUSION; CONTROLLED STUDY; DYSPHORIA; HUMAN; HUMAN EXPERIMENT; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NORMAL HUMAN; PRIORITY JOURNAL; PROFILE OF MOOD STATES; VISUAL ANALOG SCALE; ADULT; AFFECT; DRUG EFFECTS; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL;

ADULT; AFFECT; HALLUCINOGENS; HUMANS; MALE; PIPERAZINES; QUESTIONNAIRES; SEROTONIN AGONISTS; STREET DRUGS; SEROTONIN RECEPTOR AGONISTS;

EID: 77955468163     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1911-y     Document Type: Article

References (45)

1. U Antia MD Tingle BR Russell 2009 Metabolic interactions with piperazine-based 'party pill' drugs J Pharm Pharmacol 61 877 882 10.1211/jpp/61.07.0006 1:CAS:528:DC%2BD1MXpt1Wrt7o%3D 19589229
2. Antia U, Tingle MD, Russell BR (2010) Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J Forensic Sci (in press)
3. SB Auerbach N Kamalakannan JJ Rutter 1990 TFMPP and RU24969 enhance serotonin release from rat hippocampus Eur J Pharmacol 190 51 57 10.1016/0014-2999(90)94111-A 1:CAS:528:DyaK3MXhsl2guw%3D%3D 2076760
4. SB Auerbach JJ Rutter PJ Juliano 1991 Substituted piperazine and indole compounds increase extracellular serotonin in rat diencephalon as determined by in vivo microdialysis Neuropharmacology 30 307 311 10.1016/0028-3908(91)90054-F 1:CAS:528:DyaK3MXisVSmsrw%3D 1852265
5. MH Baumann DC Mash JK Staley 1995 The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain Neuroreport 6 2150 2152 10.1097/00001756-199511000-00013 1:CAS:528:DyaK28XitlOntg%3D%3D 8595191
6. MH Baumann RD Clark AG Budzynski JS Partilla BE Blough RB Rothman 2005 N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'ecstasy') Neuropsychopharmacology 30 550 560 10.1038/sj.npp.1300585 1:CAS:528:DC%2BD2MXhtlOrsbo%3D 15496938 (Pubitemid 40271157)
7. I Cloëz-Tayarani C Harel-Dupas G Fillion 1992 Inhibition of [3H] gamma-aminobutyric acid release from guinea-pig hippocampal synaptosomes by serotonergic agents Fundam Clin Pharmacol 6 333 341 10.1111/j.1472-8206.1992. tb00128.x 1292966
8. PJ Conn E Sanders-Bush 1987 Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1C) receptors J Pharmacol Exp Ther 242 652 657
9. KA Cunningham BA Carroll JB Appel 1986 Effects of repeated administration of the monoamine oxidase inhibitor phenelzine on the discriminability of d-lysergic acid diethylamide (LSD) and 1-(m-trifluoromethylphenyl) piperazine (TFMPP) Psychopharmacology 89 134 135 10.1007/BF00175206 1:CAS:528: DyaL28XltVygs7o%3D 3090587
10. G Deneau T Yanagita MH Seevers 1969 Self-administration of psychoactive substances by the monkey Psychopharmacologia 16 30 48 10.1007/BF00405254 1:CAS:528:DyaE3cXitVCmtA%3D%3D 4982648
11. Erowid Piperazine Vault (2009) Erowid experience vaults: piperazine reports. http://www.erowid.org/chemicals/piperazines
12. SN Evans 2007 The role of estradiol and progesterone in modulating the subjective effects of stimulants in humans Exp Clin Psychopharmacol 15 418 426 10.1037/1064-1297.15.5.418 1:CAS:528:DC%2BD2sXht1yiu7rL 17924776 (Pubitemid 350102229)
13. WE Fantegrossi G Winger JH Woods WL Woolverton A Coop 2005 Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys Drug Alcohol Depend 77 161 168 10.1016/j.drugalcdep.2004.07.014 1:CAS:528:DC%2BD2MXmsVCmtQ%3D%3D 15664717 (Pubitemid 40128194)
14. WE Fantegrossi KS Murnane CJ Reissig 2008 The behavioral pharmacology of hallucinogens Biochemical Pharmacology 75 17 33 10.1016/j.bcp.2007.07.018 1:CAS:528:DC%2BD2sXhsVCksLjO 17977517 (Pubitemid 350235393)
15. FDA (1997) US Food and Drug Administration postmarket drug safety information for patients and providers: FDA announces withdrawal of fenfluramine and dexfenfluramine. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm179871.htm
16. FDA (2009) US Food and Drug Administration. http://www.fda.gov
17. MF Folstein R Luria 1973 Reliability, validity, and clinical application of the Visual Analogue Mood Scale Psychol Med 3 479 486 10.1017/ S0033291700054283 1:STN:280:DyaE2c%2Flt1Gltg%3D%3D 4762224
18. RW Foltin MW Fischman 1991 Assessment of abuse liability of stimulant drugs in humans: a methodological survey Drug Alcohol Depend 28 3 48 10.1016/0376-8716(91)90052-Z 1:STN:280:DyaK3Mzls12lsA%3D%3D 1679387
19. Garattini S, Borroni E, Mennini T, Samanin R (1978) Differences and similarities among anorectic agents. In: Garattini S, Samanin R (eds) Central mechanisms of anorectic drugs. Raven, New York, pp 127-143
20. JD Griffith JG Nutt DR Jasinski 1975 A comparison of fenfluramine and amphetamine in man Clin Pharmacol Ther 18 563 570 1:STN:280: DyaE28%2Fkt1Oltg%3D%3D 1102234
21. MS Grotewiel H Chu E Sanders-Bush 1994 m-Chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts J Pharmacol Exp Ther 271 1122 1126 1:CAS:528:DyaK2MXisVyjsbo%3D 7965773
22. CA Haertzen HE Hill RE Belleville 1963 Development of the Addiction Research Center Inventory (ARCI): selection of items that are sensitive to the effects of various drugs Psychopharmacologia 4 155 166 10.1007/BF02584088 1:STN:280:DyaF2c%2Fht1arsg%3D%3D 14054658
23. A Hamik SJ Peroutka 1989 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain Biol Psychiatry 25 569 575 10.1016/0006-3223(89)90217-5 1:CAS:528:DyaL1MXhsVOkurg%3D 2537663 (Pubitemid 19071308)
24. L Herndon ME Pierson RA Glennon 1992 Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl) piperazine Pharmacol Biochem Behav 43 739 748 10.1016/0091-3057(92)90403-3 1:CAS:528:DyaK38XmsVGmsr8%3D 1333084
25. RS Kahn S Wetzler 1991 m-Chlorophenylpiperazine as a probe of serotonin function Biol Psychiatry 30 1139 1166 10.1016/0006-3223(91)90184-N 1:CAS:528:DyaK38XpvFChsw%3D%3D 1663792
26. GA Kennett G Curzon 1988 Evidence that hypophagia induced by mCPP and TFMPP requires 5-HT1C and 5-HT1B receptors; hypophagia induced by RU 24969 only requires 5-HT1B receptors Psychopharmacology 96 93 100 10.1007/BF02431539 1:CAS:528:DyaL1cXlsVeitbs%3D 2906446
27. GF Koob 1992 Neuronal mechanisms of drug reinforcement Ann N Y Acad Sci 654 171 191 10.1111/j.1749-6632.1992.tb25966.x 1:CAS:528:DyaK38XlvVCisbo%3D 1632582
28. JC Lin N Bangs HS Lee RR Kydd BR Russell 2009 Determining the subjective and physiological effects of BZP on human females Psychopharmacology 207 439 446 10.1007/s00213-009-1669-2 1:CAS:528:DC%2BD1MXhtFOitr3N 19777213
29. WR Martin JW Sloan JD Sapira DR Jasinski 1971 Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man Clin Pharmacol Ther 12 245 258 1:CAS:528:DyaE3MXhtl2gtLw%3D 5554941
30. JD McKenney RA Glennon 1986 TFMPP may produce its stimulus effects via a 5-HT1B mechanism Pharmacol Biochem Behav 24 43 47 10.1016/0091-3057(86)90042-0 1:CAS:528:DyaL28XmtF2hsg%3D%3D 3945665 (Pubitemid 16180054)
31. McNair DM, Heuchert JWP, Shilony E (2003) Research with the Profile of Mood States (POMS) 1964-2002: a comprehensive bibliography. MHC, Toronto, pp 7-8
32. F Miranda G Orozco DN Velazquez-Martinez 2002 Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist Behav Pharmacol 13 303 311 1:CAS:528:DC%2BD38Xmsl2ksLs%3D 12218511
33. Misuse of Drugs Amendment Act (2008) Classification of BZP Amendment Bill: Bill 146-2, New Zealand
34. DW Robertson W Bloomquist DT Wong ML Cohen 1992 mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors Life Sci 50 599 605 10.1016/0024-3205(92) 90372-V 1:CAS:528:DyaK38Xht1Wmtro%3D 1736030
35. RB Rothman MA Ayestas CM Dersch MH Baumann 1999 Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension Circulation 100 869 875 1:CAS:528: DyaK1MXlvFCmtbo%3D 10458725
36. RB Rothman MH Baumann CM Dersch DV Romero KC Rice FI Carroll JS Partilla 2001 Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 39 32 41 10.1002/1098-2396(20010101)39:1<32::AID-SYN5>3.0.CO;2-3 1:CAS:528:DC%2BD3cXovFahsLg%3D 11071707
37. MD Schechter 1988 Use of TFMPP stimulus properties as a model of 5-HT1B receptor activation Pharmacol Biochem Behav 31 53 57 10.1016/0091-3057(88)90310- 3 1:CAS:528:DyaL1MXmvFaktQ%3D%3D 3252260
38. P Schoeffter D Hoyer 1989 Interaction of arylpiperazines with 5-HT1A, 5-HT1B, 5-HT1C and 5-HT1D receptors: do discriminatory 5-HT1B receptor ligands exist? Naunyn Schmiedebergs Arch Pharmacol 339 675 683 10.1007/BF00168661 1:CAS:528:DyaL1MXkvFShsLk%3D 2770889
39. Sheridan J, Butler R (2007) Legal party pills and their use by young people in New Zealand: a qualitative study. Final report of findings (revised June 2007). University of Auckland, Auckland
40. J Sheridan R Butler C Wilkins B Russell 2007 Legal piperazine-containing party pills-a new trend in substance misuse Drug Alcohol Rev 26 335 343 10.1080/09595230701255791 17454024
41. M Tancer C-E Johanson 2003 Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP Drug Alcohol Depend 72 33 44 10.1016/S0376-8716(03)00172-8 1:CAS:528:DC%2BD3sXotVylsLs%3D 14563541 (Pubitemid 37255328)
42. The UK Home Office (2009) Control of 'legal highs' including GBL, BZP, synthetic cannabinoids and others. http://drugs.homeoffice.gov.uk/news-events/ latest-news/control-of-legal-highs-dec09.html
43. US Drug Enforcement Administration, Department of Justice 2002 Schedules of controlled substances: temporary placement of benzylpiperazine and trifluoromethylphenylpiperazine into Schedule I Fed Regist 67 59161 59162
44. Wilkins C, Girling M, Sweetsur P, Huckle T, Huakau J (2006) Legal party pill use in New Zealand: prevalence of use, availability, health harms and 'gateway effects' of benzylpiperazine (BZP) and triflourophenylmethylpiperazine (TFMPP). Centre for Social and Health Outcomes Research and Evaluation, Massey University, Auckland
45. JP Zacny H de Wit 1989 Effects of food deprivation on subjective responses to d-amphetamine in humans Pharmacol Biochem Behav 34 791 795 10.1016/0091-3057(89)90276-1 1:CAS:528:DyaK3cXkvVOhtA%3D%3D 2623032 (Pubitemid 20036578)